VYNDAMAX (tafamidis) 6 Dosage Forms, Strengths, Composition And Packaging

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

For Canadian
Healthcare ProfessionalsFor Canadian
Healthcare Professionals
SelectFor Canadian
Healthcare ProfessionalsFor Canadian
Healthcare Professionals
For Canadian
Patients, Consumers or CaregiversNo, go back to the patient portal
SelectFor Canadian
Patients, Consumers or CaregiversNo, go back to the patient portal
Site is intended for Canadian residents. For Non-Canada residents click here.
Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration

Dosage Form / Strength/Composition

Non-medicinal Ingredients

Oral

Capsule 61 mg: A soft gelatin capsule (filled with a white to pink suspension) contains 61 mg of micronized tafamidisAmmonium hydroxide 28%, butylated hydroxytoluene, gelatin, glycerin, iron oxide (red), polyethylene glycol 400, polysorbate 20, povidone (K value 90), polyvinyl acetate phthalate, propylene glycol, sorbitol, and titanium dioxide

VYNDAMAX (tafamidis) 61 mg: reddish brown, opaque, oblong (approximately 21 mm) capsule with “VYN 61” printed in white. Thirty (30) capsules (one-month supply) supplied in a carton of 3 blister cards. Each blister card contains 10 capsules.